These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25965177)

  • 1. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
    Jeay S; Gaulis S; Ferretti S; Bitter H; Ito M; Valat T; Murakami M; Ruetz S; Guthy DA; Rynn C; Jensen MR; Wiesmann M; Kallen J; Furet P; Gessier F; Holzer P; Masuya K; Würthner J; Halilovic E; Hofmann F; Sellers WR; Graus Porta D
    Elife; 2015 May; 4():. PubMed ID: 25965177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
    Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
    Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
    Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
    Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A signature for success.
    Espinosa JM; Sullivan KD
    Elife; 2015 Jun; 4():. PubMed ID: 26079875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
    Holzer P; Masuya K; Furet P; Kallen J; Valat-Stachyra T; Ferretti S; Berghausen J; Bouisset-Leonard M; Buschmann N; Pissot-Soldermann C; Rynn C; Ruetz S; Stutz S; Chène P; Jeay S; Gessier F
    J Med Chem; 2015 Aug; 58(16):6348-58. PubMed ID: 26181851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
    Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
    Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.
    Furet P; Masuya K; Kallen J; Stachyra-Valat T; Ruetz S; Guagnano V; Holzer P; Mah R; Stutz S; Vaupel A; Chène P; Jeay S; Schlapbach A
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4837-4841. PubMed ID: 27542305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
    Bauer S; Demetri GD; Halilovic E; Dummer R; Meille C; Tan DSW; Guerreiro N; Jullion A; Ferretti S; Jeay S; Van Bree L; Hourcade-Potelleret F; Wuerthner JU; Fabre C; Cassier PA
    Br J Cancer; 2021 Aug; 125(5):687-698. PubMed ID: 34140638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
    Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
    Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance.
    Zhang M; Chen XY; Dong XD; Wang JQ; Feng W; Teng QX; Cui Q; Li J; Li XQ; Chen ZS
    Front Oncol; 2020; 10():1219. PubMed ID: 32793491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors.
    Sonkin D
    Elife; 2015 Oct; 4():. PubMed ID: 26491944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control.
    Sánchez-Aguilera A; García JF; Sánchez-Beato M; Piris MA
    Oncogene; 2006 Apr; 25(18):2565-74. PubMed ID: 16331255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
    Jeay S; Gaulis S; Ferretti S; Bitter H; Ito M; Valat T; Murakami M; Ruetz S; Guthy DA; Rynn C; Jensen MR; Wiesmann M; Kallen J; Furet P; Gessier F; Holzer P; Masuya K; Würthner J; Halilovic E; Hofmann F; Sellers WR; Graus Porta D
    Elife; 2016 Nov; 5():. PubMed ID: 27852439
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer Drugs.
    Holzer P
    Chimia (Aarau); 2017 Oct; 71(10):716-721. PubMed ID: 29070416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network perspectives on HDM2 inhibitor chemotherapy combinations.
    Azmi AS; Beck FW; Sarkar FH; Mohammad RM
    Curr Pharm Des; 2011; 17(6):640-52. PubMed ID: 21391913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.
    LaRusch GA; Jackson MW; Dunbar JD; Warren RS; Donner DB; Mayo LD
    Cancer Res; 2007 Jan; 67(2):450-4. PubMed ID: 17234751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hdm2 and nitric oxide radicals contribute to the p53-dependent radioadaptive response.
    Takahashi A; Matsumoto H; Ohnishi T
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):550-8. PubMed ID: 18410999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.